Eledon Pharmaceuticals Gains FDA End-of-Phase 2 Alignment for Tegoprubart Ahead of Global Phase 3 Kidney Trial

With an End-of-Phase 2 FDA meeting now concluded, Eledon Pharmaceuticals has locked in the regulatory framework that will govern CMC planning, trial design, and manufacturing scale-up for tegoprubart's entry into a global Phase 3 kidney transplantation program targeted for late-2026 initiation. For QA directors and regulatory leads already tracking novel immunosuppressant pipelines, the alignment signals that agency expectations around comparator selection, endpoint architecture, and safety monitoring are settled.

The planned Phase 3 trial will enroll approximately 600 patients across global sites, with a primary endpoint of non-inferiority versus tacrolimus at 52 weeks on a composite of biopsy-proven acute rejection (BPAR), graft loss, and death. That comparator choice and endpoint structure will directly inform process validation requirements and the analytical method packages needed to support a future Biologics License Application or NDA submission. Manufacturing teams should note that the scale-up timeline is compressed: trial initiation is less than five months out from the Q2 reporting date.

Supporting the Phase 3 rationale, long-term Phase 2 BESTOW data presented at the American Transplant Congress in June 2026 showed a statistically significant eGFR separation at 18 months, with tegoprubart-treated patients averaging approximately 74 mL/min/1.73 m² versus 61 mL/min/1.73 m² for tacrolimus (p<0.05). No BPAR events were observed in the tegoprubart arm after the first six months post-transplant, compared with seven events in 9.4% of tacrolimus-treated patients. The BESTOW extension data also reported favorable long-term safety and tolerability, a profile relevant to the risk-benefit documentation regulators will expect in the Phase 3 protocol submission.

On the supply-chain and bioanalytical side, Eledon has entered a partnership with Natera, Inc. to deploy Natera's Prospera donor-derived cell-free DNA (dd-cfDNA) assay as the exclusive monitoring tool in the Phase 3 trial. Integrating a proprietary assay as a protocol-specified diagnostic adds a vendor qualification and data-integrity layer that QA teams will need to address under 21 CFR Part 211 and ICH Q10 quality system expectations before site activation.

Separately, updated islet cell transplantation data from a University of Chicago Medicine investigator-initiated study, presented at ADA 2026, showed all 12 Type 1 diabetes patients achieving insulin independence with HbA1c below 6.5% and no nephrotoxicity or hypertension signals through 22 months of follow-up. While outside the Phase 3 scope, the safety profile across two transplant settings strengthens the pharmacovigilance dataset that will underpin the global trial's safety reporting framework.

Eledon reported cash, cash equivalents, and short-term investments of $88.8 million as of June 30, 2026, a runway figure that regulatory and operations leads will read against the capital requirements of a 600-patient global trial and the CMC deliverables due before first patient in.

Source: Eledon Pharmaceuticals via GlobeNewswire, August 13, 2026.